Nanoviricides, Inc. (NNVC) — 10-K Filings
All 10-K filings from Nanoviricides, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
NanoViricides' Lead Drug NV-387 Clears Phase I, Eyes Broad-Spectrum Antiviral Market
— Sep 29, 2025 Risk: high
NanoViricides, Inc. (NNVC) is a clinical-stage biopharmaceutical company that reported no revenues or profitable operations for the fiscal year ended June 30, 2 -
NanoViricides Reports FY24 Results, R&D Investment Continues
— Sep 27, 2024 Risk: medium
NanoViricides, Inc. filed its 10-K for the fiscal year ending June 30, 2024, reporting significant research and development expenses. The company's financial st
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX